secwatch.observer — SEC 8-K summary
======================================

Issuer:     Keros Therapeutics, Inc. (KROS)
CIK:        0001664710
Form:       8-K
Filed at:   2023-04-19T23:59:59+00:00
Accession:  0001664710-23-000025
Event type: leadership
Sentiment:  neutral
Materiality: 0.25
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Keros Therapeutics appoints Alpna Seth, Ph.D., to board effective May 1, 2023
-----------------------------------------------------------------------------

- Board increased to eight members; Dr. Seth appointed as Class II director with term through 2025 annual meeting.
- Dr. Seth will serve on the Compensation Committee.
- Initial option grant of 20,000 shares vesting quarterly over three years; annual retainer $40,000 (board) plus $6,000 (committee).
- Dr. Seth previously CEO of Nura Bio, COO of Vir Biotechnology, and SVP at Biogen.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1664710/000166471023000025/0001664710-23-000025-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1664710/000166471023000025/kros-20230413.htm
  HTML page:      https://secwatch.observer/filing/0001664710-23-000025

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer